Trial · NCT04331054
Protective Role of Inhaled Steroids for Covid-19 Infection
NCT04331054, Phase 3, Terminated, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Protective Role of Inhaled Steroids for Covid-19 Infection. Trials, record NCT04331054. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04331054
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Protective Role of Inhaled Steroids for Covid-19 Infection
- NCT number
- NCT04331054
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 146 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Covid-19 Infection, Hospitalization in Respiratory Disease Department
- Interventions
- 2: Usual practice + SYMBICORT RAPIHALER, 1: Usual practice
- First posted
- 2020-04-02
- Last updated
- 2021-08-03
- Other registries' IDs
- eudract:2020-001306-35
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time (in days) to clinical improvement within 30 days after randomization | within 30 days | Time (in days) to clinical improvement is defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first within 30 days. The seven-category ordinal scale consisted of the following categories: 1. Not hospitalized with resumption of normal activities 2. Not hospitalized, but unable to resume normal activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 6. Hospitalized, requiring ECMO, invasive mechanical ventilation, or both 7. Death. These parameters will be evaluated daily during hospitalization. |
| Secondary | Mortality rate at D30 | At day30 | |
| Secondary | Time (in days) from randomization to death | up to 30 days after randomization | |
| Secondary | Number of days alive outside ICU within 30 days | At day30 | |
| Secondary | Number of days alive free of invasive or non-invasive ventilation within 30 days | At day30 | |
| Secondary | Number of days alive with oxygen therapy within 30 days | At day30 | |
| Secondary | Maximal oxygen rate within 30 days | At day30 | |
| Secondary | Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7) | at Day 7 | |
| Secondary | Number of days alive outside hospital within 30 days | at Day 30 | |
| Secondary | Use of antibiotics for respiratory (proved or suspected) infection within 30 days | at Day 30 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04331054
GET https://conductscience.org/api/trials/v1/NCT04331054/registered